Status:

RECRUITING

Ambulatory Long Length URodynamics Evaluation

Lead Sponsor:

Bright Uro

Conditions:

Urology

Urinary Bladder, Overactive

Eligibility:

All Genders

22+ years

Phase:

NA

Brief Summary

A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.

Detailed Description

Subjects will have the Glean Urodynamics System inserted for an in-clinic ambulatory monitoring period. Afterward, they will be discharged with the Glean Bladder Sensor in place for continued monitori...

Eligibility Criteria

Inclusion Criteria:

  1. Male or female patient must be ≥ 22 years of age.
  2. Patient is a candidate for UDS per standard of care.
  3. Patient is able to provide informed consent.

Exclusion Criteria:

  1. Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and/or dysuria).
  2. Patient has a history of recurrent UTIs (≥ 3 episodes in previous 12 months).
  3. Patient has used antibiotics within the past 7 days from the baseline/screening visit.
  4. Patient diagnosed with neurogenic LUTD (i.e., one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).
  5. Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).
  6. Patient with a urostomy.
  7. Patient with a colostomy.
  8. Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and/or bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures).
  9. Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).
  10. Patient with any abnormal or concerning rectal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, or active yeast infections.
  11. Patient has a known inability to void.
  12. Patient has a previous history of radiation leading to bleeding (e.g., hemorrhagic radiation cystitis).
  13. Patient is pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months, or intending to become pregnant during the study period.
  14. Patients who may not be able to independently use a smart device.
  15. Subjects who, at the principal investigator's determination, would not be appropriate for this study.

Key Trial Info

Start Date :

February 17 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2027

Estimated Enrollment :

101 Patients enrolled

Trial Details

Trial ID

NCT07425015

Start Date

February 17 2026

End Date

June 1 2027

Last Update

April 15 2026

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Chesapeake Urology Associates

Hanover, Maryland, United States, 21076

2

Chesapeake Urology Associates

Owings Mills, Maryland, United States, 21117

3

Urology of St. Louis

St Louis, Missouri, United States, 63141

4

MetroHealth

Cleveland, Ohio, United States, 44109